Argenx’s I.V. Vyvgart May See Continued Role In ITP, Despite SubQ Version Coming

A subcutaneous formulation of argenx N.V.’s Vyvgart (efgartigimod alfa-fcab) – currently available as an intravenous drug – would no doubt benefit patients from a convenience standpoint. However, the intravenous formulation may continue to have significant utility as the company works to expand its labeling into primary immune thrombocytopenia (ITP), a type of rare platelet disorder.

The company presented updated data from its pivotal Phase III ADVANCE study of Vyvgart in ITP during an 11 December plenary session at the American Society of Hematology annual meeting in New Orleans. Vyvgart, a neonatal Fc receptor blocker, won US Food and Drug Administration approval in December 2021 for generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor antibody-positive, and it has since seen a successful launch